Lipoproteins: From physiological roles to drug delivery potentials

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 23, Issue 6, 2006, Pages 497-523

  Hamidi, Mehrdad ^a   Foroozesh, Mahshid ^a   Zarrin, Abdolhossein ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Lipoprotein carrier; Lipoproteins; Particulate carrier systems

Indexed keywords

ACLACINOMYCIN; ACLARUBICIN; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CHYLOMICRON; DAUNORUBICIN DERIVATIVE; DEXAMETHASONE DERIVATIVE; DOXORUBICIN; DRUG CARRIER; ELLIPTINIUM; FLOXURIDINE; FLUOROURACIL; HEMATOPORPHYRIN; HIGH DENSITY LIPOPROTEIN; IDOXURIDINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METHOTREXATE; PACLITAXEL; PHTHALOCYANINE ALUMINUM; PHTHALOCYANINE ZINC; PRIMAQUINE; THYMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VERY LOW DENSITY LIPOPROTEIN; VINDESINE; WARFARIN HEXADECYL ETHER; WB 4291; ZIDOVUDINE;

ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; DRUG ISOLATION; DRUG TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; LIPID METABOLISM; LIPOPHILICITY; LIQUID; MACROMOLECULE; MYCOSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICULATE MATTER; PHOTODYNAMIC THERAPY; PHYSIOLOGY; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION;

EID: 34147151148     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v23.i6.20     Document Type: Review

References (97)

1. La Van DA, Mc Guire T, Langer R. Small scale systems for in vivo drug delivery. Nature Biotechnol. 2003;21(10):1184-91.
2. Bramwell VW, Perrie Y. Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst. 2005;22(2):151-214.
3. Gregoriadis G. Liposome technology. Volumes 1-3. Boca Raton, FL: CRS Press, 1993.
4. Yagi K. Medical applications of liposomes. Tokyo: Scientific Press and Basel: Karger, 1986.
5. Schmidt KH. Liposomes as drug carriers. Stuttgart: Georg Thieme Verlag, 1986.
6. Hofheinz RD. Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs. 2005;16(7):691-707.
7. Goyal P, Goyal K, Vijaya Kumar SC, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems - clinical applications. Acta Pharm. 2005;55(1):1-25.
8. Hu C, Rhodes DG. Proniosomes: A novel drug carrier preparation. Int J Pharm. 2000;206(1-2):110-22.
9. Huang YZ, Han G, Wang H, Liang WQ. Cationic niosomes as gene carriers: preparation and cellular uptake in vitro. Pharmazie. 2005;60(6):473-4.
10. Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol. 2005;18(5):209-19.
11. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Master Res A. 2006;77(2):351-61.
12. Williams D. Small is beautiful: microparticle and nanoparticle technology in medical devices. Med Device Technol. 1999;10(3):6-9.
13. Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug delivery. Adv Drug Deliv Rev. 2004;56(11):1621-33.
14. Prevo BG, Velev OD. Controlled, rapid deposition of structured coatings from micro- and nanoparticle suspensions. Langmuir. 2004;20(6):2099-107.
15. Hamidi M, Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv. 2003;10(1):9-20.
16. Rossi L, Serafini S, Pierige F, Antonelli A, Cerasi A, Fraternale A, Chiarantini L, Magnani M. Erythrocyte-based drug delivery. Expert Opin Drug Deliv. 2005;2(2):311-22.
17. Millan CG, Marinero ML, Castaneda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release. 2004;95(1):27-49.
18. Ihler GM, Tsang HC. Erythrocyte carriers. Crit Rev Ther Drug Carrier Syst. 1985;1 (2):155-87.
19. Kurz M, Gu K, Al-Gawari A, Lohse PL. cDNA - protein fusions: covalent protein - gene conjugates for the in vitro selection of peptides and proteins. Chembiochem. 2001;2(9):666-72.
20. Dilgimen AS, Mustafaeva Z, Demchenko M, Kaneko T, Osada Y, Mustafaev M. Water-soluble covalent conjugates of bovine serum albumin with anionic poly(N-isopropyl-acrylamide) and their immunogenicity. Biomaterials. 2001;22 (17):2383-92.
21. Bolbach, G. Matrix-assisted laser desorption/ionization analysis of non-covalent complexes: fundamentals and applications. Curr Pharm Des. 2005;11(20):2535-57.
22. Vrkic AK, O'Hair RA. Using non-covalent complexes to direct the fragmentation of glycosidic bonds in the gas phase. J Am Soc Mass Spectrom. 2004;15(5);715-24.
23. Havel RJ. Lipid transport function of lipoproteins in blood plasma. Am J Physiol. 1987;253 (1 pt 1);E1-E5.
24. Bauer JE. Lipoprotein-mediated transport of dietary and synthesized lipids and lipid abnormalities of dogs and cats. J Am Vet Med Assoc. 2004;224(5):668-75.
25. Grundy SM, Dobson HL, Kitzmiller GE, Griffin AC. Lipid transport and lipoprotein interconversions. J Am Physiol. 1961;200:1307-10.
26. Scanu AM, Scandiani L. Lipoprotein (a): structure, biology, and clinical relevance. Adv Intern Med. 1991;36:249-70.
27. Forte T, Nichols AV. Application of electron microscopy to the study of plasma lipoprotein structure. Adv Lipid Res. 1972;10:1-41.
28. Cushley RJ, Okon M. NMR studies of lipoprotein structure. Ann Rev Biophys Biomol Struct. 2002;31:177-206.
29. Lund-Katz S, Liu L, Thuahnai ST, Phillips MC. High density lipoprotein structure. Front Biosci. 2003;8:d1044-54.
30. Jackson RL, Morrisett JD, Jr., Gotto AM. Lipoprotein structure and metabolism. Physiol Rev. 1976;56(2):259-316.
31. Hevonoja T, Pentikainen MO, Hyvonen MT, Kovanen PT, Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000;1488(3):189-210.
32. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev. 2001;47(2-3):251-76.
33. Hardman, JG, Limbird, LE, Goodman Gilman, A. Goodman and Gilman's The pharmacological basis of therapeutics. 10 ed. New York: McGraw Hill, 2001.
34. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/ilmonen/table2.gif
35. Campos EM. From Fredrickson's classification of phenotypes-lipoprotein patterns-to genotype comprehension. Acta Med Port. 2005;18(3):189-98.
36. Yoshida A, Kodama M, Nomura H, Naito M. Classification of lipoprotein profile by polyacrylamide gel disc electrophoresis. Intern Med. 2003;42(3):244-9.
37. Bickerstaffe R, Desmond FB. Lipoprotein classification by analytical ultracentrifugation. Pathology. 1982;14(2):165-71.
38. Lewis B. Classification of lipoproteins and lipoprotein disorders. J Clin Pathol Suppl (Assoc Clin Pathol). 1973;5:26-31.
39. http://www.fao.org/docrep/ V4700E/V4700E09.GIF
40. Trigatti BL. Hepatic high-density lipoprotein receptors: roles in lipoprotein metabolism and potential for therapeutic modulation. Curr Atheroscler Rep. 2005;7(5):334-50.
41. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 2004;24(10):1750-4.
42. Pauciullo P. Lipoprotein transport and metabolism: a brief update. Nutr Metab Cardiovasc Dis. 2002;12(2):90-7.
43. Beisiegel U. Lipoprotein metabolism. Eur Heart J. 1998;19(SupplA);A20-3.
44. Hammel M, Laggner P, Prassl R. Structural characterization of nucleoside loaded low-density lipoprotein as a main criterion for the applicability as drug delivery system. Chem Phys Lipids. 2003;123(2):193-207.
45. Banker, GS Rhodes, CT. Modern pharmaceutics, 4 ed. New York: Marcel Dekker Inc, 2002.
46. de Smidt PC, van Berkel TJ. LDL-mediated drug targeting. Crit Rev™ Ther Drug Carrier Syst. 1990;7(2):99-120.
47. Hara T, Tan Y, Huang L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. Proc Natl Acad Sci USA. 1997;94(26):14547-52.
48. Kader A, Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release. 2002;80(1-3):29-44.
49. Masquelier M, Vitols S, Palsson M, Mars U, Larsson BS, Peterson CO. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J Drug Target. 2000;8(3):155-64.
50. Samadi-Baboli M, Favre G, Canal P, Soula G. Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer. 1993;68(2):319-26.
51. Lestavel-Delattre S, Martin-Nizard F, Clavey V, Testard P, Favre G, Doualin G, Houssaini HS, Bard JM, Duriez P, Delbart C. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 1992;52(13):3629-35.
52. Favre G. Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives. CR Seances Soc Biol Fil. 1992;186:73-87.
53. Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002;22(4):2045-9.
54. Motta PM. The three-dimensional fine structure of the liver as revealed by scanning electron microscopy. Int Rev Cytol Suppl. 1977;6:347-99.
55. Wisse E, Braet F, Luo D, de Zanger R, Jans D, Crabbe E, Vermoesen A. Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol. 1996;24(1):100-11.
56. Dierling AM, Cui Z. Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int J Pharm. 2005;303(1-2):143- 52.
57. Mankertz J, Matthes E, Rokos K, von Baeyer H, Pauli G, Riedel E. Selective endocytosis of fluorothymidine and azidothymidine coupled to LDL into HIV infected mononuclear cells. Biochim Biophys Acta. 1996;1317(3):233-7.
58. Schumaker VN, Puppione DL. Sequential floatation ultracentrifugation. Methods Enzymol. 1986;128:155-70.
59. Rodriguez-Sureda V, Julve J, Llobera M, Peinado-Onsurbe J. Ultracentrifugation micromethod for preparation of small experimental animal lipoproteins. Anal Biochem. 2002;303(1):73-7.
60. Kader A, Davis PJ, Kara M, Liu H. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J Control Release. 1998;55(2-3):231-43.
61. Burstein, M, Scholnick HR. Lipoprotein polyanion metal interactions. Ada Lipid Res. 1973;11:67-108.
62. Perrier H, Perrier C, Peres G, Gras J. The lipoproteins of the plasma of the rainbow trout (Salmo gairdneri): immunoelectrophoresis. selective precipitation and lipid composition. Comp Biochem Physiol. 1979;62B:245-8.
63. Masquelier M, Vitols S, Peterson C. Low density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. 1986;46:3842-7.
64. de Smidt PC, van Berkel TJ. Prolonged serum half-life of antineoplastic drugs by incorporation into the low-density lipoprotein. Cancer Res. 1990;50(23):7476-82.
65. Tauchi Y, Zushida L, Yokota M, Chono S, Sato J, Ito K, Morimoto K. Inhibitory effect of dexamethasone palmitate-low density lipoprotein complex on low density lipoprotein-induced macrophage foam cell formation. Biol Pharm Bull. 2000;23:466-71.
66. van Berkel TJ. Drug targeting: application of endogenous carriers for site specific delivery of drug. J Control Release. 1993;24:145-55.
67. Firestone RA. Low density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem. 1994;5:105-13.
68. Filipowska D, Filipowski T, Morelowska B, Kazanowska W, Laudanski T, Lapinjoki S, Akerlund M, Breeze A. Treatment of cancer patients with a low density lipoprotein vehicle containing a cytotoxic drug. Cancer Chemother Pharmacol. 1992;29:396-400.
69. Koller-Lucae SK, Schott H, Schwendener RA. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D- arabinofuranosyl cytosine in Daudi lymphoma cells. Br J Cancer. 1999;80(10):1542-9.
70. Shawer M, Greenspan P, OIe S, Lu DR. VLDL-resembling phospholipid- submicron emulsion for cholesterol-based drug targeting. J Pharm Sci. 2002;91(6):1405-13.
71. von Baeyer H, Neitzel H, Nundel M, Riedel E, Schultis HK. Covalent coupling of nucleosides to low density lipoprotein (LDL) generates macrophage specific (drug)-carriers. Int J Clin Pharmacol Ther Toxicol. 1993;31(8):382-6.
72. Tokui T, Kuroiwa C, Muramatsu S, Tokui Y, Sasagawa K, Ikeda T, Komai T. Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice. Biopharm Drug Dispos. 1995;16(2):91-103.
73. Gerke A, Westesen K, Koch MH. Physicochemical characterization of protein-free low density lipoprotein models and influence of drug loading. Pharm Res. 1996;13(1):44-51.
74. Hu J, Liu H, Wang L. Enhanced delivery of AZT to macrophages via acetylated LDL. J Control Release. 2000;69(3):327-35.
75. Mankertz J, Nundel M, von Baeyer H, Riedel E. Low-density lipoproteins as drug carriers in the therapy of macrophage-associated diseases. Biochem Biophys Res Commun 1997;240(1):112-5.
76. Bijsterbosch MK, Ziere GJ, van Berkel TJ. Lactosylated low density lipoprotein: A potential carrier for site-specific delivery of drugs to kupffer cells. Mol Pharmacol. 1989;36(3):484-9.
77. Bijsterbosch MK, Ziere GJ, van Berkel TJ. Lactosylated high density lipoprotein: A potential carrier for site-specific delivery of drugs to parenchymal liver cells. Mol Pharmacol. 1992;41(2):404-11.
78. Rutherford MS, Jr. Futch WS, Schook LB. Acetylated low density lipoprotein and the delivery of immunomodulators to macrophages. Targeted Diagn Ther. 1991;5:201-223
79. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D. HIV infection and high-density lipoprotein: the effect of the disease vs. the effect of treatment. Metabolism. 2006;55(1):90-5.
80. Squalli-Houssaini H, Pierlot C, Kusnierz JP, Parmentier B, Martin-Nizard F, Lestavel-Delattre S, Tartar A, Fruchart JC, Sergheraert C, Duriez P. Preparation of anti-HIV-low-density lipoprotein complexes for delivery of anti-HIV drugs via the low density lipoprotein pathways. Biotechnol Ther. 1994;5(1-2):69-85.
81. Samadi-Baboli M, Favre G, Blancy E, Soula G. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro. Eur J Cancer Clin Oncol. 1989;25(2):233-41.
82. Reddi E, Zhou C, Biolo R, Menegaldo E, Jori G. Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency. Br J Cancer. 1990;61(3):407-11.
83. Hamblin MR, Newman EL. Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins. J Photochem Photobiol B. 1994;26(2):147-57.
84. Schmidt-Erfurth U, Diddens H, Birngruber R, Hasan T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer. 1997;75(1):54-61.
85. de Vries HE, Moor AC, Dubbelman TM, van Berkel TJ, Kuiper J. Oxidized low-density lipoprotein as a delivery system for photosensitizers: implications for photodynamic therapy of atherosclerosis. J Pharmacol Exp Ther. 1999;289(1):528-34.
86. Xiao W, Wang L, Ryan JM, Pater A, Liu H. Incorporation of an (125)I-labeled hexa-iodinated diglyceride analog into low-density lipoprotein and high specific uptake by cells of cervical carcinoma cell lines. Radiat Res. 1999;152(3):250-6.
87. Masquelier M, Tirzitis G, Peterson CO, Palsson M, Amolins A, Plotniece M, Plotniece A, Makarova N, Vitols SG. Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur J Med Chem. 2000;35(4):429-38.
88. Tauchi Y, Zushida L, Chono S, Sato J, Ito K, Morimoto K. Effect of dexamethasone palmitate-low density lipoprotein complex on cholesterol ester accumulation in aorta of atherogenic model mice. Biol Pharm Bull. 2001;24(8):925-9.
89. Li W, Xi S, Zhang M. The cytotoxic effect of a low density lipoprotein delivered aclarubicin on leukemia cells. Zhonghua Xue Ye Xue Za Zhi. 2001;22(12):636-8.
90. Tauchi Y, Chono S, Morimoto K. Cellular uptake of a dexamethasone palmitate-low density lipoprotein complex by macrophages and foam cells. J Drug Target. 2003;11(3):163-8.
91. Khan Z, Hawtrey AO, Ariatti M. New cationized LDL-DNA complexes: their targeted delivery to fibroblasts in culture. Drug Deliv. 2003;10(3):213-20.
92. Martins J, Almeida L, Laranjinha J. Simultaneous production of superoxide radical and singlet oxygen by sulphonated chloroaluminum phthalocyanine incorporated in human low-density lipoproteins: implications for photodynamic therapy. Photochem Photobiol. 2004;80(2):267-73.
93. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA. 2005;102(49):17757-62.
94. Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. : World J Gastroenterol. 2005;11(7):954-9.
95. Li H, Marotta DE, Kim S, Busch TM, Wileyto EP, Zheng G. High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. J Biomed Opt. 2005;10(4):41203.
96. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res. 2006;47(2):260-7.
97. Masquelier M, Lundberg B, Peterson C, Vitols S. Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells. Leuk Res. 2006;30(2):136-44.